|
|
||||||||
The Journal of Immunology, Vol 131, Issue 1 180-185, Copyright © 1983 by American Association of Immunologists
ARTICLES |
PJ Martin, G Longton, JA Ledbetter, W Newman, MP Braun, PG Beatty and JA Hansen
The structural and functional domains of Tp50, the human T lymphocyte surface protein associated with the E rosette receptor, were probed with the use of two murine monoclonal antibodies. Lysostripping, immune precipitation, and competitive binding experiments demonstrated that antibodies 9.6 and 35.1 bind to Tp50 epitopes in close proximity. In functional studies, both antibodies caused a similar degree of antigenic modulation, inhibited T cell proliferative responses, and inhibited cytotoxic T lymphocyte function without affecting cells that mediate antibody-dependent cell-mediated cytotoxicity. The antibodies were strikingly different, however, in that antibody 9.6 inhibited E rosette formation and natural killer cell-mediated lysis, whereas antibody 35.1 did not. These results could not be ascribed to differences in antibody class or binding characteristics, because Scatchard analysis demonstrated that these two IgG2a antibodies have comparable avidity and that T cells bind each antibody in equivalent amounts. The differential binding of antibodies 9.6 and 35.1 to T cells from nonhuman primates further supports the interpretation that the differences between the antibodies in their effects on E rosette formation and natural killer function stem from the fact that they bind to distinct epitopes of Tp50. The implications of these findings for understanding the functions of Tp50 molecules are discussed.
This article has been cited by other articles:
![]() |
J. E. Hutchcroft, J. M. Slavik, H. Lin, T. Watanabe, and B. E. Bierer Uncoupling Activation-Dependent HS1 Phosphorylation from Nuclear Factor of Activated T Cells Transcriptional Activation in Jurkat T Cells: Differential Signaling Through CD3 and the Costimulatory Receptors CD2 and CD28 J. Immunol., November 1, 1998; 161(9): 4506 - 4512. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |